(Press-News.org) (Singapore – 10:05 a.m. SGT--September 11, 2023) – A modified adenocarcinoma classification approach significantly enhances reproducibility and may be an improvement on the existing World Health Organization classification system, according to research unveiled at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
The study, led by Dr. Erik Thunnissen, Department of Pathology, Amsterdam UMC, VU Medical Center, Amsterdam, The Netherlands, was born out of the IASLC Pathology Committee’s acknowledgment of challenges in accurately assigning invasion status based on the criteria outlined in the World Health Organization (WHO) classification of pulmonary adenocarcinomas. The objective was to establish a baseline and investigate the potential for an improved classification system, aided by biomarker analysis.
Dr. Thunnissen and colleagues conducted a case-control study involving resected adenocarcinomas measuring up to 3 cm (n=70), the research evaluated the potential of a modified classification system. The modified classification factored in iatrogenic collapsed adenocarcinoma in situ, identified through elastin and cytokeratin 7 staining. Pathologists initially assessed the cases according to the WHO criteria and then underwent a tutorial, after which they scored the cases based on the modified classification. A heatmap analysis was conducted to identify areas commonly or less frequently identified as invasive.
The study drew participation from 42 pathologists across 13 countries who scored the cases in three rounds. The kappa values for the three rounds were 0.27, 0.45, and 0.62, respectively. These results indicated that the standard WHO criteria for determining invasion faced challenges in achieving consistent and reproducible results.
However, the modified classification exhibited notably higher reproducibility. Pathologists displayed a more significant increase in competence, reflected by a higher kappa score, both when evaluated blindly (0.45) and with guidance (0.62). The outcomes suggested that the revised classification overcomes the limitations of the WHO criteria, thereby addressing concerns about inconsistent assessments.
Importantly, the research revealed that cases scored with "no-invasion" consensus in the second and third rounds achieved a 100% recurrence-free survival (RFS) rate. The diagnosis of adenocarcinoma in situ after resection with the modified classification implies that the patient is cured. In contrast, with the diagnosis of invasive adenocarcinoma in these cases based on the WHO classification, the patient has to bear the anxiety of a chance of recurrence.
Further bolstering the modified classification, biomarker analyses associated with invasion and poor outcomes were conducted. These analyses unveiled intriguing correlations, including a low proliferation rate in adenocarcinoma in situ compared to invasive adenocarcinomas and the presence of TP53 mutations in invasive adenocarcinomas, underscoring their role as late-stage events.
"Our findings suggest that the modified adenocarcinoma classification significantly enhances reproducibility and aligns better with the clinical reality. These results open new avenues for refining our understanding of these cancers and improving patient care,” Dr. Thunnissen reported.
"These findings could enable a more confident diagnosis and treatment decisions for patients with pulmonary adenocarcinomas,” he said.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.
About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration, and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2023.iaslc.org.
END
Large-scale investigation supports modified classification system for pulmonary adenocarcinomas
2023-09-11
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Taiwan launches National Lung Cancer Early Detection Program detects 85 percent of lung cancer cases at early phase
2023-09-11
First-ever National Screening Program to Consider Family History
(Singapore – 10:05 a.m. SGT--September 11, 2023) – The Taiwan National Lung Cancer Early Detection Program detected 85 percent of lung cancer cases at either a phase 0 or phase 1 level, demonstrating that lung cancer screening can detect lung cancer at an early enough phase to allow doctors to intervene more effectively.
The results of the program were presented by Pan-Chyr Yang, MD, PhD from the National Taiwan University Hospital, at the International Association for the Study of Lung Cancer 2023 World Conference ...
Surgical outcomes of perioperative durvalumab in AEGEAN study to be presented at IASLC 2023 World Conference on Lung Cancer
2023-09-11
[Singapore, 10:05 a.m. SGT--September 11, 2023] – Adding perioperative durvalumab to neoadjuvant chemotherapy did not adversely impact surgery in patients with resectable NSCLC and was associated with a tolerable surgical safety profile, according to research presented today from the phase 3 AEGEAN trial at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore.
"The AEGEAN trial demonstrated a clinically meaningful improvement in EFS ...
Treatment for dangerous snoring prevents deaths from heart disease
2023-09-11
Milan, Italy: People suffering with obstructive sleep apnoea (OSA) can reduce their risk of dying from cardiovascular disease if they use a continuous positive airway pressure (CPAP) machine at night, according to research presented at the European Respiratory Society International Congress in Milan, Italy [1].
CPAP may also work better than a weight loss drug in reducing the build-up of plaque in the arteries around the heart, according to a pilot study also presented at the European Respiratory Society International Congress [2].
People with OSA often snore loudly, their breathing starts and stops during the night, and they may ...
City living raises the risk of respiratory infections in babies and young children
2023-09-11
Milan, Italy: Young children growing up in towns and cities suffer from more respiratory infections than those who grow up in the countryside, according to research presented at the European Respiratory Society International Congress in Milan, Italy [1].
A second study, presented at the Congress and published in Pediatric Pulmonology today (Monday) [2], shows that factors such as attending day care, living in a damp home or near dense traffic increase the risk of chest infections in young children, while breastfeeding reduces the risk.
Researchers say that some children, who are otherwise healthy, can suffer with repeated infections, so it is important to understand why ...
Healthy guts containing diverse and mature bacteria are linked to less allergy-related wheezing and asthma in early childhood
2023-09-10
Milan, Italy: Babies and young children with more mature communities of bacteria present in their gut are less likely to develop allergy-related wheezing or asthma, according to research presented at the European Respiratory Society International Congress in Milan, Italy [1].
These communities of bacteria, known as microbiota, develop in the human body during the early years of life and are involved in processes that are helpful to the body, such as synthesising vitamins and boosting the immune system, or occasionally unhelpful, such as the role they play ...
Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension
2023-09-10
About The Study: Among individuals with uncontrolled hypertension in this randomized clinical trial that included 200 participants, use of lorundrostat was effective at lowering blood pressure compared with placebo, which will require further confirmatory studies.
Authors: Steven E. Nissen, M.D., of the Cleveland Clinic Foundation, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.16029)
Editor’s Note: Please see the article for additional ...
Benmelstobart plus anlotinib and chemotherapy shows benefit for patients with extensive-stage small-cell lung cancer
2023-09-10
[Singapore -- 10:35 a.m. SGT--September 10, 2023] - The combination of benmelstobart, anlotinib, and chemotherapy demonstrated significant benefits compared to placebo and chemotherapy in terms of median progression-free survival and overall survival for patients with extensive-stage small-cell lung cancer.
The research was presented today at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer in Singapore.
Extensive-stage small-cell lung cancer is a challenging malignancy to treat, ...
Exhaled breath analysis shows promise in detecting malignant pleural mesothelioma
2023-09-10
[Singapore -- 10:35 a.m. SGT--September 10, 2023] -- Identifying and analyzing volatile organic compounds in exhaled breath of patients with malignant pleural mesothelioma showed promise as a screening method for MPM, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
Malignant pleural mesothelioma (MPM) is a challenging disease with limited treatment options and a poor prognosis. To improve ...
Six-year follow-up data on CheckMate 227 survival and quality of life benefits unveiled for patients with metastatic NSCLC and nivolumab + ipilimumab treatment
2023-09-10
[Singapore -- 10:35 a.m. SGT--September 10, 2023) -- The International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore is set to witness a monumental breakthrough in the field of metastatic non-small cell lung cancer (NSCLC) treatment. Research findings from the CheckMate 227 trial will be presented, shedding light on the extraordinary six-year survival and quality of life benefits associated with first-line nivolumab + ipilimumab therapy.
CheckMate 227 Part 1 showed that a combination ...
KRYSTAL-1 trial finds that adagrasib demonstrates durable clinical activity in patients with KRAS-G12C mutations
2023-09-10
[Singapore -- 10:35 a.m. SGT--September 10, 2023] — The oral, selective KRAS G12C inhibitor The oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at two years, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
KRAS-G12C mutations occur in approximately 14% of patients with NSCLC. The KRYSTAL-1 study, a multi-cohort Phase 1/2 trial, evaluated adagrasib as a monotherapy or in combination for patients with KRAS-G12C-mutated ...